Alkermes (ALKS) Net Cash Flow Growth (3y) (2013 - 2026)
Alkermes (ALKS) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -49.94% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -62.71% |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | -205.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -205.66% |
| Dec 31, 2025 | 160.37% |
| Sep 30, 2025 | 117.08% |
| Jun 30, 2025 | 85.17% |
| Mar 31, 2025 | 58.42% |
| Dec 31, 2024 | -80.49% |
| Sep 30, 2024 | -67.09% |
| Jun 30, 2024 | 28.98% |
| Mar 31, 2024 | 18.54% |
| Dec 31, 2023 | -99.39% |
| Sep 30, 2023 | -32.93% |
| Jun 30, 2023 | 198.60% |
| Mar 31, 2023 | 44.93% |
| Dec 31, 2022 | 35.62% |
| Sep 30, 2022 | -47.80% |
| Jun 30, 2022 | 1.58% |
| Mar 31, 2022 | -9.81% |
| Dec 31, 2021 | -18.86% |
| Sep 30, 2021 | -4.70% |
| Jun 30, 2021 | 55.21% |